# US 2009/0269345 A1 · CLN248 Antibody Compositions and Methods of Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269345 A1
- Document ID: US20090269345A1
- Status: Published application
- Kind: A1
- Application number: 12/158,729
- Filed: 2006-12-22
- Published: 2009-10-29
- Earliest claimed: 2005-12-23
- Inventors: Rong Fan; Nam Kim; Robert L. Wolfert
- Web page: https://patentgrep.com/patent/US20090269345A1

## CPC

- C07K 16/3046: {Stomach, Intestines}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Isolated anti-Cln248 antibodies that bind to Cln248 and cells that produce the anti-Cln248 antibodies are provided. Also provided are compositions of an anti-Cln248 antibody and a carrier. In addition, isolated nucleic acids encoding an anti-Cln248 antibody, as well as an expression vector for the isolated nucleic acids are provided. Methods for identifying anti-Cln248 antibodies, methods for producing the anti-Cln248 antibodies, as well as methods for their use in killing a Cln248-expressing cancer cells and alleviating or treating a Cln248-expressing cancer in a mammal are also provided.

## Claims

### Claim 1

An antibody which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma selected from the group of hybridomas in Table 1.

### Claim 2 (depends on 1)

The antibody of claim 1 which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by hybridomas PTA-7172 or PTA-7175.

### Claim 3 (depends on 1)

The antibody of claim 1 which is an antibody fragment, a monoclonal, a human, a chimeric or a humanized antibody.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 1)

The antibody of claim 1 which binds a Cln248 peptide, wherein said peptide comprises Val29 to His300 of Cln248, a post translational modification, motif, or domain.

### Claim 7

(canceled)

### Claim 8 (depends on 6)

The antibody of claim 6 wherein the post translational modification, motif, or domain is an EGF-like domain signature 2 or a TNFR/NGFR cysteine-rich region.

### Claim 9 (depends on 1)

The antibody of claim 1 where the antibody competes for binding with FasL, LIGHT or TL1A.

### Claim 10 (depends on 3)

The antibody of claim 3 which is produced by a hybridoma deposited with the American Type Culture Collection selected from the group consisting of PTA-7172 and PTA-7175 or which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection selected from the group consisting of PTA-7172 and PTA-7175.

### Claim 11

(canceled)

### Claim 12 (depends on 3)

The antibody of claim 3 which is conjugated to a growth inhibitory agent or a cytotoxic agent.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

The antibody of claim 12 wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

### Claim 15 (depends on 3)

The antibody of claim 3 wherein the antibody is detectably labeled.

### Claim at position 15

16-17. (canceled)

### Claim 18 (depends on 1)

The antibody of claim 1 where the antibody inhibits the growth of Cln248-expressing cancer cells.

### Claim at position 17

19-21. (canceled)

### Claim 22 (depends on 18)

The antibody of claim 18, wherein the cancer cells are from a cancer selected from the group consisting of colon, ovarian, lung and prostate cancer or a metastatic colon, ovarian, lung or prostate cancer.

### Claim 23 (depends on 3)

A cell that produces the antibody of claim 3.

### Claim 24 (depends on 23)

The cell of claim 23, wherein the cell is selected from the group consisting of a hybridoma deposited with the American Type Culture Collection selected from the group consisting of PTA-7172 and PTA-7175.

### Claim 25

(canceled)

### Claim 26 (depends on 3)

A composition comprising the antibody of claim 3, and a carrier.

### Claim at position 23

27-29. (canceled)

### Claim 30 (depends on 26)

The composition of claim 26, wherein the antibody is an antibody produced by hybridoma deposited with the American Type Culture Collection selected from the group consisting of PTA-7172 and PTA-7175 or an antibody which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection selected from the group consisting of PTA-7172 and PTA-7175.

### Claim 31 (depends on 1)

A method of killing a Cln248-expressing cancer cell, comprising binding Cln248 with the antibody of claim 1, thereby inhibiting Cln248 activity and killing the cancer cell.

### Claim 32 (depends on 31)

The method of claim 31, wherein the cancer cell is selected from the group consisting of a colon, ovarian, lung and prostate cancer cell or a metastatic colon, ovarian, lung or prostate cancer.

### Claim at position 27

33-34. (canceled)

### Claim 35 (depends on 31)

The method of claim 31, wherein the antibody is an antibody fragment, a monoclonal, a human, a chimeric or a humanized antibody.

### Claim 36

(canceled)

### Claim 37 (depends on 31)

The method of claim 31, wherein the antibody is conjugated to a cytotoxic agent or a growth inhibitory agent.

### Claim at position 31

38-39. (canceled)

### Claim 40 (depends on 31)

The method of claim 31, wherein the antibody is a humanized form of the antibody produced by hybridoma deposited with the American Type Culture Collection selected from the group consisting of PTA-7172 and PTA-7175 or an antibody which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection selected from the group consisting of PTA-7172 and PTA-7175.

### Claim 41 (depends on 18)

A method of alleviating an Cln248-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the antibody of claim 18 to the mammal.

### Claim 42 (depends on 41)

The method of claim 41, wherein the cancer is selected from the group consisting of colon, ovarian, lung and prostate cancer or a metastatic colon, ovarian, lung or prostate cancer.

### Claim at position 35

43-45. (canceled)

### Claim 46 (depends on 41)

The method of claim 41, wherein the antibody is administered in conjunction with at least one chemotherapeutic agent.

### Claim 47

(canceled)

### Claim 48 (depends on 3)

An article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an antibody of claim 3.

### Claim 49

(canceled)

### Claim 50 (depends on 3)

A method for determining if cells in a sample express Cln248 comprising
(a) contacting a sample of cells with an Cln248 antibody of claim 3 under conditions suitable for specific binding of the Cln248 antibody to Cln248, and
(b) determining the level of binding of the antibody to Cln248 in the sample, or the level of Cln248 antibody internalization by cells in said sample,
wherein Cln248 antibody binding to Cln248 in the sample or internalization of the Cln248 antibody by cells in the sample indicate cells in the sample express Cln248.

### Claim 51 (depends on 50)

The method of claim 50 wherein said sample of cells are contacted with an antibody produced by a hybridoma deposited with the American Type Culture Collection selected from the group consisting of PTA-7172 and PTA-7175 or an antibody which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection selected from the group consisting of PTA-7172 and PTA-7175.

### Claim 52 (depends on 50)

The method of claim 50 wherein
said sample of cells is from a subject who has a cancer, is suspected of having a cancer or who may have a predisposition for developing cancer.

### Claim 53 (depends on 52)

The method of claim 52 wherein the cancer is a colon, ovarian, lung or prostate cancer or a metastatic colon, ovarian, lung or prostate cancer.

### Claim at position 44

54-59. (canceled)

### Claim 60 (depends on 3)

A method for detecting Cln248 overexpression in a subject in need thereof comprising,
(a) combining a sample from a subject with an Cln248 antibody of claim 3 under conditions suitable for specific binding of the Cln248 antibody to Cln248 in said bodily fluid sample,
(b) determining the level of Cln248 in the sample, and
(c) comparing the level of Cln248 determined in step
(b) to the level of Cln248 in a control,
wherein an increase in the level of Cln248 in the sample from the subject as compared to the control is indicative of Cln248 overexpression in the subject.

### Claim 61 (depends on 60)

The method of claim 60 wherein the subject has cancer.

### Claim 62 (depends on 61)

The method of claim 61
wherein the subject has colon, ovarian, lung or prostate cancer or a metastatic colon, ovarian, lung or prostate cancer.

### Claim 63

(canceled)

### Claim 64 (depends on 60)

The method of claim 60, wherein the sample from the subject is selected from the group consisting of bodily fluids, cells, cancer cells, blood, serum, plasma, urine, ascites, peritoneal wash, saliva, sputum, seminal fluids, mucous membrane secretions, and other bodily excretions such as stool.

### Claim 65 (depends on 60)

The method of claim 60 wherein the control is a bodily fluid sample or cell sample from a subject without a cancer overexpressing Cln248 or a sample of known concentration of Cln248.

### Claim 66

(canceled)

### Claim 67 (depends on 60)

The method of claim 60 wherein two Cln248 antibodies are utilized in a sandwich ELISA format.

### Claim 68 (depends on 67)

The method of claim 67 wherein the ELISA has a MDC of 21 pg/mL.

### Claim 69 (depends on 67)

The method of claim 67 wherein the Cln248 antibodies produced by hybridomas deposited with the American Type Culture Collection selected from the group consisting of PTA-7172 and PTA-7175 or an antibody which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma deposited with the American Type Culture Collection selected from the group consisting of PTA-7172 and PTA-7175.

### Claim 70 (depends on 3)

A screening method for antibodies that bind to an epitope which is bound by an antibody of claim 3 comprising,
(a) combining an Cln248-containing sample with a test antibody and an antibody of claim 3 to form a mixture,
(b) determining the level of Cln248 antibody bound to Cln248 in the mixture, and (c) comparing the level of Cln248 antibody bound in the mixture of step (a) to a control mixture,
wherein the level of Cln248 antibody binding to Cln248 in the mixture as compared to the control is indicative of the test antibody's binding to an epitope that is bound by the anti-Cln248 antibody of claim 3.

### Claim 71

(canceled)

### Claim 72 (depends on 70)

The screening method of claim 70 wherein the control is a mixture of Cln248, a monoclonal antibody which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma selected from the group of hybridomas in Table 1 and an antibody known to bind the epitope bound by said monoclonal antibody.

### Claim at position 58

73-75. (canceled)
